Media Center

All news News

  • 17 July 2018

    Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

    Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

    Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the  American Society of Retina Specialists ,  July 20-25  in  Vancouver, Canada . 

  • 11 July 2018

    Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs

    Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs

    learside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Carol Hoang , Pharm.D., MBA, to the position of Vice President, Medical Affairs.

  • 10 July 2018

    Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer

    Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer

    An international team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Epic Sciences, The Institute of Cancer Research, UK, and London Health Sciences Centre, Canada, have shown that a blood test can identify patients with metastatic castration resistant prostate cancer (mCRPC) who may live longer if they switch from targeted androgen receptor-signaling inhibitor (ARSi) therapy, such as enzalutamide and abiraterone, to taxane-based chemotherapy. This independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit. 

  • 21 June 2018

    Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index

    Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced that it will be added to the Russell 2000® and Russell 3000® Indexes, effective Friday, June 22, 2018, after market close. 

  • 19 June 2018

    Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder

    Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the initiation of a pivotal Phase 3 clinical trial (Marigold Study) evaluating the use of oral ganaxolone in children and young adults with CDKL5 Deficiency Disorder (CDD).

  • 15 June 2018

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 90,000 shares of its common stock to two new employees, with a grant date of  June 14, 2018 .

  • 14 June 2018

    Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced completion of patient enrollment in a Phase 3 clinical trial (“SAPPHIRE”) of suprachoroidal CLS-TA used in combination with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) for the treatment of Retinal Vein Occlusion (“RVO”).

  • 31 May 2018

    Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced positive topline results from its Phase 2 clinical trial (“TYBEE”) evaluating suprachoroidal CLS-TA used with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) in patients with diabetic macular edema (“DME”) over a 6-month evaluation period.

  • 30 May 2018

    Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration

    Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2018 . In addition, the Company provided a clinical and business update. As of  March 31, 2018 , Syndax had  $113.2 million  in cash, cash equivalents and short-term investments.

  • 24 May 2018

    Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants

    Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants

    Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced the closing of its previously announced underwritten public offering of 8.5 million shares of common stock or, in lieu of shares of common stock, pre-funded warrants exercisable for shares of common stock, and accompanying common warrants to purchase an aggregate of 1.7 million shares of common stock. At closing, Evofem received net proceeds from the offering of approximately $36.4 million, after deducting offering expenses. All of the securities in the offering were sold by Evofem.

All publications Media about us